Growth Capitalist (https://growthcapitalist.com/tag/biotech/page/66/)
Retrophin, Inc. (RTRX) announced that it has raised $40,000,000 in a Non-Convertible Term Notes transaction. Barclays Capital, Inc. acted as the exclusive agent on the transaction. The investor was Athyrium Capital Management, LLC. This Placement is part of a $80 million financing. The other $40 million was funded in the form of Convertible Notes.
OXiGENE Inc. (OXGN) announced that it has raised $16,000,009 in a Registered Direct transaction. The common stock was sold at $2.96 per share, an approximate 1% discount to the market price ($2.98) of OXGN at deal announcement. A series of 2,700,424 63-Month Warrants with an exercise price of $2.90 per share (2.68% discount) was issued to the investors in this transaction. H.C. Wainwright & Co., LLC acted as the exclusive agent on the transaction. Placement Agent counsel was Ellenoff Grossman & Schole LLP and issuer counsel was Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, PC.
AEterna Zentaris Inc. (AEZS) announced that it has secured up to $15,000,000 in an ATM (At the Market) transaction with MLV & Co. LLC. The purchase price is the prevailing market price at the time of the Draw Down Notice. Placement Agent counsel was LeClairRyan, PC and issuer counsels were Norton Rose Fulbright and Ropes & Gray. via PlacementTracker.
RepliCel Life Sciences, Inc. (REPCF) announced that it has raised $2,567,070 in a Units (Common Stock + Warrants) transaction. The common stock was sold at $0.69 per share, an approximate 5% premium to the market price ($0.66) of REPCF at deal announcement. A series of 3,717,167 24-Month Warrants with an exercise price of $0.92 per share (39.52% premium) was issued to the investors in this transaction. Wolverton Securities Limited acted as the exclusive agent on the transaction. The transaction closed on May 09, 2014.
